Sorrento rises as experimental drug shows promise against Omicron
28/01/2022 15:03
** Sorrento Therapeutics' shares SRNE.O rise ~3% to $2.96
** Says its experimental oral drug, STI-1558, neutralizes
Omicron variant of coronavirus in lab tests urn:newsml:reuters.com:*:nGNX3TmQNs
** Two brokerages covering SRNE rate the stock "buy"; their
median PT is $22
** Despite session's gain, stock down 36% YTD
(Reporting by Leroy Leo)
((Leroy.Dsouza@thomsonreuters.com;))
Recent news on Sorrento Therapeutics
See all newsBrief: Scilex Holding Says US Bankruptcy Court Extended Lockup Period On Shares Of Scilex Stock
Company's PO box allows it to file for bankruptcy in Texas, judge rules
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute (updated)
Latham, Jackson Walker avoid sanctions over bankruptcy forum shopping dispute
Brief: Sorrento Therapeutics Reduced U.S. Headcount From 215 To 128 on Sept. 20